Nkarta (NKTX) Projected to Post Earnings on Wednesday

Key Points

• Nkarta will report Q1 2026 results before the market opens on May 13, with analysts forecasting ($0.39) EPS; the company missed estimates last quarter (reported ($0.37) vs. consensus ($0.32)).
• Shares recently traded around $3.08 with a 52‑week range of $1.63–$3.65 and a market cap of $219.57 million; the stock has a negative P/E and institutional ownership of 80.54%.
• Analyst coverage is mixed: MarketBeat shows a consensus rating of Hold with an average target price of $11.33 (three Buys, one Hold, one Sell), alongside several recent target and rating changes.

Nkarta (NASDAQ:NKTX - Get Free Report) is expected to be releasing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Nkarta to post earnings of ($0.39) per share for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, analysts expect Nkarta to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nkarta Price Performance

Nkarta stock opened at $3.08 on Wednesday. Nkarta has a 1-year low of $1.63 and a 1-year high of $3.65. The business has a fifty day moving average price of $2.50 and a 200-day moving average price of $2.19. The stock has a market capitalization of $219.57 million, a price-to-earnings ratio of -2.20 and a beta of 0.88.

Institutional Trading of Nkarta

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NKTX. Abel Hall LLC acquired a new position in shares of Nkarta in the fourth quarter valued at about $27,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Nkarta in the fourth quarter worth about $37,000. Wells Fargo & Company MN lifted its holdings in shares of Nkarta by 45.8% during the fourth quarter. Wells Fargo & Company MN now owns 47,997 shares of the company's stock worth $89,000 after purchasing an additional 15,079 shares during the period. Man Group plc purchased a new stake in Nkarta in the third quarter valued at approximately $90,000. Finally, Prelude Capital Management LLC purchased a new stake in Nkarta in the third quarter valued at approximately $90,000. Institutional investors and hedge funds own 80.54% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on NKTX shares. Needham & Company LLC increased their price target on Nkarta from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Thursday, March 26th. Wall Street Zen downgraded shares of Nkarta from a "hold" rating to a "sell" rating in a report on Saturday, March 28th. Mizuho decreased their price objective on shares of Nkarta from $14.00 to $12.00 and set an "outperform" rating for the company in a research report on Tuesday, March 31st. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Nkarta in a research note on Friday, March 27th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Nkarta currently has a consensus rating of "Hold" and an average target price of $11.33.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company's platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta's lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.